ModifiedmhnPolicy CP.PHAR.216

Factor VIII/von Willebrand Factor Complex (Human Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant Vonvendi)

Prior authorization policy describing medical necessity criteria, documentation requirements, and approval durations for Alphanate, Humate‑P, Wilate, and Vonvendi for Hemophilia A and von Willebrand disease across commercial, HIM, and Medicaid lines of business.

Policy Summary

Payermhn

PolicyFactor VIII/von Willebrand Factor Complex (Alphanate, Humate‑P, Wilate) and Vonvendi (recombinant vWF)

Policy CodePolicy CP.PHAR.216

Change TypeMaterial revisions (desmopressin step age thresholdauthorization duration and indication updates)

Effective DateMay 1, 2016

Next Review Date

Key ActionSubmit prior authorization with clinical documentation (office notes, labs, weight in kg) demonstrating medical necessity and meeting step therapy requirements such as a desmopressin trial when applicable.

SourceLink

POLICY UPDATE CHANGES

Revised desmopressin acetate trial requirement to apply only for age ≥ 2 years.

Extended initial and continued authorization durations for hemophilia and von Willebrand disease prophylaxis from 3 months to 12 months for HIM Texas.

Added newly approved indication for Vonvendi for routine prophylaxis and pediatric extension for on‑demand and perioperative treatment.

For continued therapy clarified that current weight is only needed if a higher dose is being requested.

4products requiring prior authorization

2primary diagnoses covered

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

desmopressin age threshold

Up to 12 moprophylaxis authorization (selected LOBs)

J7183,J7186,J7187,J7179HCPCS codes referenced

Coverage Criteria

Initial Therapy — Congenital Hemophilia A

Covered when ALL of the following are met for Congenital Hemophilia A

Hemophilia A initial criteria: 1. Diagnosis of congenital hemophilia A (FVIII deficiency); 2. Request is for Alphanate, Humate‑P, or Wilate; 3. Prescribed by or in consultation with a hematologist; 4. Request is for one of the following uses: a. Control or prevention of bleeding episodes; b. Perioperative management (Alphanate only); c. Routine prophylaxis to reduce the frequency of bleeding episodes (Wilate only); 5. For routine prophylaxis requests (Wilate only) for members who have not previously used Wilate for routine prophylaxis, member meets one of the following: a. Severe hemophilia (FVIII < 1%); b. At least one serious spontaneous bleed; 6. For age ≥ 2 years AND FVIII coagulant activity > 5%: failure of desmopressin acetate unless contraindicated, clinically significant adverse effects occur, or an appropriate formulation is unavailable (Illinois HIM carve‑out noted); 7. Documentation of member's current body weight (kg); 8. Dose does not exceed the FDA‑approved maximum recommended dose for the relevant indication.

Initial Therapy — Von Willebrand Disease

Covered when ALL of the following are met for Von Willebrand Disease

VWD initial criteria: 1. Diagnosis of von Willebrand disease (VWD); 2. Prescribed by or in consultation with a hematologist; 3. For age ≥ 2 years AND VWD type 1 or 2 (except type 2B): failure of desmopressin acetate unless contraindicated, clinically significant adverse effects occur, or an appropriate formulation is unavailable (Illinois HIM carve‑out noted); 4. Request is for one of the following uses: a. Treatment of bleeding episodes (Humate‑P, Vonvendi, and Wilate only); b. Perioperative management; c. Routine prophylaxis to reduce the frequency of bleeding episodes and one of: i. Request is for Vonvendi and age ≥ 18 years; ii. Request is for Wilate and age ≥ 6 years; 5. Documentation of member's current body weight (kg); 6. Dose does not exceed the FDA‑approved maximum recommended dose for the relevant indication.

Continuation Therapy

Covered when ALL of the following are met for continuation therapy

Continuation criteria: 1. Member meets one of the following: a. Currently receiving medication via the Centene benefit or previously met initial approval criteria; b. Currently receiving medication and enrolled in a state/product with continuity of care regulations; 2. Member is responding positively to therapy; 3. If request is for a dose increase: a. Documentation of member's current body weight in kg (if requesting a higher dose than previously requested); b. New dose does not exceed the FDA‑approved maximum recommended dose for the relevant indication.

Other diagnoses/indications

When requested use is not specifically listed

Other indications pathway: 1. If the drug has had a recent label change (within the last 6 months) not yet reflected in this policy, follow either: a. For drugs on the formulary/PDL: the no coverage criteria policy for the relevant line of business (CP.CPA.190 commercial / HIM.PA.33 HIM / CP.PMN.255 Medicaid); b. For drugs not on the formulary/PDL: the non‑formulary policy for the relevant line of business (CP.CPA.190 commercial / HIM.PA.103 HIM / CP.PMN.16 Medicaid); 2. If the requested use (diagnosis, age, dosing) is not listed under section III and criterion 1 does not apply, refer to the off‑label use policy for the relevant line of business (CP.CPA.09 commercial / HIM.PA.154 HIM / CP.PMN.53 Medicaid).

Indication-based coverage

Coverage is product- and indication-specific with dosing tiers for minor, moderate, major, perioperative, and prophylactic uses.

Product indications: Alphanate, Humate‑P, Wilate, and Vonvendi are covered for control and prevention of bleeding in Hemophilia A and VWD per their indicated dosing regimens; Vonvendi also has indications for routine prophylaxis and pediatric extensions as noted in dosing and administration sections.

See product‑specific dosing regimens and FDA maximum doses in the Dosage and Administration section of the policy.

Alphanate is not indicated for use in patients with severe von Willebrand disease (type 3) who are undergoing major surgery.

Contraindications include patients with known hypersensitivity reactions, including anaphylactic or severe systemic reactions, to human plasma-derived products, any ingredient in the formulation, or components of the container. For Vonvendi, contraindication applies to patients with a history of life‑threatening hypersensitivity reactions to Vonvendi or its components. Boxed warnings: none reported.

Coverage determinations under this clinical policy are intended as a guide to medical necessity and do not constitute a contract or guarantee of payment. All decisions are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, or policy), as well as applicable state and federal requirements and Health Plan-level administrative policies and procedures.

Requests for off‑label or non‑FDA approved indications that are not specifically addressed in this policy will not be authorized unless the provider submits sufficient documentation demonstrating efficacy and safety consistent with the applicable off‑label use policy (see CP.CPA.09 for Commercial, HIM.PA.154 for Marketplace, or CP.PMN.53 for Medicaid) or per evidence of coverage documents.

Listing of codes in this clinical policy is for informational purposes only. Inclusion of a code does not guarantee coverage; claims must meet the Health Plan’s medical necessity requirements and include adequate clinical documentation to support reimbursement. Providers should use current professional coding guidance when submitting claims.

Coding and Codes

Products requiring prior authorizationNDC | product names

Alphanate	Factor VIII/von Willebrand factor complex (human)
Humate‑P	Factor VIII/von Willebrand factor complex (human)
Wilate	Factor VIII/von Willebrand factor complex (human)
Vonvendi	Recombinant von Willebrand factor

Therapeutic alternativesmixed

desmopressin acetate

Therapeutic alternative (Stimate nasal spray; generic injection solution)

Relevant HCPCS CodesHCPCS

J7183	Injection, von Willebrand factor complex (human), Wilate, 1 IU vWF:RCo.
J7186	Injection, antihemophilic FVIII/von Willebrand factor complex (human), per FVIII i.u. (Alphanate).
J7187	Injection, von Willebrand factor complex (Humate-P), per IU VWF:RCO.
J7179	Injection, von Willebrand factor (recombinant), (Vonvendi), per 1 IU vWF:rco

inv-14: Age threshold for desmopressin step — 9 2 years

Age thresholdDesmopressin step therapy applies for patients aged ≥ 2 years

Applies to diagnosesHemophilia A (when FVIII >5%) and VWD type 1 or 2 (except 2B)

Illinois HIM exceptionStep therapy requirement does not apply to Illinois HIM requests as of 1/1/2026 per IL HB 5395

inv-15: FVIII activity threshold for desmopressin use 6 > 5% FVIII coagulant activity

FVIII activity threshold> 5% FVIII coagulant activity required to consider a desmopressin trial before factor products

Context of use

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Alphanate, Humate‑P, Vonvendi, and Wilate. Provider must document that the member meets medical necessity criteria per the Health Plan clinical policy and administrative guidelines.

Prior authorization required for Alphanate, Humate‑P, Vonvendi, and Wilate.

Documentation Required

Required Clinical Documentation

Providers must submit clinical documentation (office chart notes, lab results, prior therapy documentation, and other relevant clinical information) to support that the member meets all approval criteria. Documentation must align with Health Plan administrative policies and coverage documents.

Include office notes and relevant laboratory results.
If requesting a dose increase, include prior dosing history and rationale.

Background

Factor VIII/von Willebrand factor concentrates (plasma‑derived complexes such as Alphanate, Humate‑P, and Wilate) and recombinant von Willebrand factor (Vonvendi) are used to treat bleeding disorders including Hemophilia A (FVIII deficiency) and von Willebrand disease (VWD). These products are indicated for control and prevention of bleeding episodes, perioperative management, and, for select products and populations, routine prophylaxis. Desmopressin acetate (DDAVP) is an alternative therapy for certain patients (for example, some VWD or mild Hemophilia A) and is a required prior trial in specified situations unless contraindicated, not tolerated, or unavailable.

Definitions

inv-31: DDAVP 6 Desmopressin acetate definition

TermDDAVP

DefinitionDesmopressin acetate

NotesListed in Appendix A as the abbreviation for desmopressin acetate (therapeutic alternative)

inv-32: Routine prophylaxis 6 Ongoing administration to reduce frequency of bleeding episodes

DefinitionRoutine prophylaxis: ongoing administration to reduce the frequency of bleeding episodes

Use casesUsed to reduce recurrent bleeding frequency in patients with Hemophilia A or VWD when product labeling supports prophylaxis

Policy Summary

Payermhn

PolicyFactor VIII/von Willebrand Factor Complex (Alphanate, Humate‑P, Wilate) and Vonvendi (recombinant vWF)

Policy CodePolicy CP.PHAR.216

Change TypeMaterial revisions (desmopressin step age thresholdauthorization duration and indication updates)

Effective DateMay 1, 2016

Next Review Date

SourceLink

On This Page

Applies when requesting factor products for Hemophilia A routine prophylaxis or treatment per initial criteria

ExceptionIf desmopressin is contraindicated, causes clinically significant adverse effects, or an appropriate formulation is unavailable, the requirement may be waived

inv-16: Dose maxima and regimens

Alphanate maximumMaximum dose: 100 IU/kg/day (dosing: minor 15 IU/kg q12h; moderate 25 IU/kg q12h; major 40-50 IU/kg initial then 25 IU/kg q12h)

Humate-P maximumMaximum dose: 240 IU/kg/day (dosing examples include moderate 25 IU/kg loading then 15 IU/kg q8-12h; major 40-50 IU/kg initial then 20-25 IU/kg q8h)

Wilate maximumMaximum dose: 150 IU/kg/day (dosing: minor/moderate 30-40 IU/kg q12-24h; major 35-50 IU/kg q12-24h; routine prophylaxis 20-40 IU/kg every 2-3 days)

Vonvendi maximaMinor episodes max 150 IU/kg/day; major episodes max 180 IU/kg/day; perioperative maxima: minor surgeries 60 IU/kg/day, major surgeries 120 IU/kg/day; prophylaxis initiation 40-60 IU/kg twice weekly (max 60 IU/kg twice weekly)

Documentation Required

Weight Documentation Required

Provide the member's current body weight in kilograms for all initial requests; for continued therapy, include current weight only if requesting a higher dose than previously approved. Weight is required for dosing calculations and absence of weight may risk denial.

Document member weight in kg on initial requests.
For dose increases, include current body weight in kg.
Requests lacking weight when required may be denied.

Step Therapy

Step Therapy and Bypass Requirements

Step therapy requires a prior trial of desmopressin acetate for applicable patients (age ≥ 2 years with FVIII activity > 5% for Hemophilia A or VWD type 1 or 2 except 2B) unless contraindicated or clinically inappropriate. Recent regulatory updates (e.g., IL HB 5395) implement step therapy bypasses for specified lines of business — verify applicable state/line-specific exceptions.

Desmopressin trial required for age ≥ 2 years when clinically applicable.
For Illinois HIM, step therapy exceptions/bypass may apply per IL HB 5395 (effective dates referenced in policy).
If desmopressin is contraindicated, document reason(s) for inability to trial.

inv-33: Serious bleeding episode 6 Definition entry

DefinitionSerious bleeding episode: bleeds in critical sites such as intracranial; neck/throat; gastrointestinal; joints (hemarthrosis); muscles (deep compartments); or mucous membranes of mouth, nose, and genitourinary tract

RelevanceUsed in criteria to determine need for prophylaxis (e.g., prior serious spontaneous bleed supports Wilate prophylaxis)

SourceAppendix D general information lists examples of serious bleeding sites

inv-34: Spontaneous bleed 6 Definition entry

DefinitionSpontaneous bleed: a bleeding episode that occurs without apparent cause and is not the result of trauma

ContextPresence of at least one serious spontaneous bleed can qualify a member for routine prophylaxis with Wilate if other criteria met

SourceDefined in Appendix D of the policy

inv-35: Health Plan 6 Definition of the health plan operating or administering the policy

DefinitionHealth Plan: a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates

ImplicationCoverage decisions are subject to the member's coverage documents and Health Plan-level administrative policies

Non-contractual natureThis clinical policy is a guide to medical necessity and does not constitute a contract or guarantee of payment